Literature DB >> 20634213

Neuregulin-1beta1 rapidly modulates nitric oxide synthesis and calcium handling in rat cardiomyocytes.

Alessia Brero1, Roberta Ramella, Amandine Fitou, Claudio Dati, Giuseppe Alloatti, Maria Pia Gallo, Renzo Levi.   

Abstract

AIMS: The ErbB-neuregulin-1β1 (Nrg1β1) pathway is required for cardiac development and exerts chronic effects on the postnatal adult heart. Long-term application of Nrg1β1 results in hypertrophy and protection against oxidative stress and cytotoxic agents. We performed experiments with acute Nrg1β1 treatment to find evidence for a further protective role due to rapid modulation of adult cardiomyocyte function. METHODS AND
RESULTS: In confocal fluorimetric measurements, Nrg1β1 induced a calcium-independent increase in nitric oxide (NO) production in isolated adult rat ventricular myocytes (ARVCMs) that was blocked by the phosphoinositide-3-kinase (PI3K) inhibitor Wortmannin. Western blot analysis showed enhancement of endothelial nitric oxide synthase phosphorylation in Nrg1β1-treated ARVCMs, which was attenuated by Wortmannin. Nrg1β1 induced a significant increase in calcium transient amplitude (indo-1 ratiometric measurement) and accelerated the recovery of cytosolic calcium in the sarcoplasmic reticulum without affecting whole-cell L-type calcium current. Wortmannin or the protein kinase G inhibiting peptide (DT-2) abolished the increase in calcium transient amplitude and the acceleration of calcium recovery induced by Nrg1β1 treatment. Immunofluorescence analysis revealed that Nrg1β1 treatment increased phospholamban phosphorylation, and the effect was blocked by PI3K and protein kinase G inhibition. Caffeine-releasable sarcoplasmic reticulum calcium content was also higher during Nrg1β1 administration.
CONCLUSION: Rapid activation of PI3K, endothelial nitric oxide synthase and protein kinase G and a consequent improvement in diastolic calcium can be added to established Nrg1 protective roles.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20634213     DOI: 10.1093/cvr/cvq238

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  23 in total

Review 1.  The role of neuregulin/ErbB2/ErbB4 signaling in the heart with special focus on effects on cardiomyocyte proliferation.

Authors:  Brian Wadugu; Bernhard Kühn
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-03-16       Impact factor: 4.733

2.  A pharmacological investigation of Hippophae salicifolia (HS) and Hippophae rhamnoides turkestanica (HRT) against multiple stress (C-H-R): an experimental study using rat model.

Authors:  Richa Rathor; Priyanka Sharma; Geetha Suryakumar; Lilly Ganju
Journal:  Cell Stress Chaperones       Date:  2015-06-05       Impact factor: 3.667

Review 3.  Signalling between microvascular endothelium and cardiomyocytes through neuregulin.

Authors:  Emily M Parodi; Bernhard Kuhn
Journal:  Cardiovasc Res       Date:  2014-01-29       Impact factor: 10.787

4.  A bioengineered hydrogel system enables targeted and sustained intramyocardial delivery of neuregulin, activating the cardiomyocyte cell cycle and enhancing ventricular function in a murine model of ischemic cardiomyopathy.

Authors:  Jeffrey E Cohen; Brendan P Purcell; John W MacArthur; Anbin Mu; Yasuhiro Shudo; Jay B Patel; Christopher M Brusalis; Alen Trubelja; Alexander S Fairman; Bryan B Edwards; Mollie S Davis; George Hung; William Hiesinger; Pavan Atluri; Kenneth B Margulies; Jason A Burdick; Y Joseph Woo
Journal:  Circ Heart Fail       Date:  2014-06-05       Impact factor: 8.790

5.  Bidirectional cross-regulation between ErbB2 and β-adrenergic signalling pathways.

Authors:  Polina Sysa-Shah; Carlo G Tocchetti; Manveen Gupta; Peter P Rainer; Xiaoxu Shen; Byung-Hak Kang; Frances Belmonte; Jian Li; Yi Xu; Xin Guo; Djahida Bedja; Wei Dong Gao; Nazareno Paolocci; Rutwik Rath; Douglas B Sawyer; Sathyamangla V Naga Prasad; Kathleen Gabrielson
Journal:  Cardiovasc Res       Date:  2015-12-21       Impact factor: 10.787

Review 6.  Neuregulin-1β for the treatment of systolic heart failure.

Authors:  Douglas B Sawyer; Anthony Caggiano
Journal:  J Mol Cell Cardiol       Date:  2011-06-28       Impact factor: 5.000

Review 7.  Neuregulin as a heart failure therapy and mediator of reverse remodeling.

Authors:  Cristi L Galindo; Sergey Ryzhov; Douglas B Sawyer
Journal:  Curr Heart Fail Rep       Date:  2014-03

Review 8.  The potential role of aerobic exercise to modulate cardiotoxicity of molecularly targeted cancer therapeutics.

Authors:  Jessica M Scott; Susan Lakoski; John R Mackey; Pamela S Douglas; Mark J Haykowsky; Lee W Jones
Journal:  Oncologist       Date:  2013-01-18

Review 9.  Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues.

Authors:  Michel G Khouri; Pamela S Douglas; John R Mackey; Miguel Martin; Jessica M Scott; Marielle Scherrer-Crosbie; Lee W Jones
Journal:  Circulation       Date:  2012-12-04       Impact factor: 29.690

Review 10.  Neuregulin in cardiovascular development and disease.

Authors:  Oghenerukevwe Odiete; Michael F Hill; Douglas B Sawyer
Journal:  Circ Res       Date:  2012-10-26       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.